Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
Provided By GlobeNewswire
Last update: Mar 26, 2025
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea
Emrosi Initial Distribution Ongoing; First Prescriptions Filled
Read more at globenewswire.com6.95
-0.31 (-4.27%)
2.12
+0.16 (+8.16%)
Find more stocks in the Stock Screener
DERM Latest News and Analysis
